Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECITE: Romiplostim for Chemotherapy-induced Thrombocytopenia in Oxaliplatin-based Chemotherapy
2023-507148-35-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Romiplostim arm with Placebo arm (2 arms). Primary endpoint: No thrombocytopenia-induced modification of chemotherapy in cycles 2 and 3. Started Nov 2023; status: completed.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2023-507148-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507148-35-00.